CIK 1510580

Kite Pharma, Inc.

EDGAR filings

Customers

None disclosed

Suppliers

0 disclosed

Latest period

Sep 30, 2020

10-Q filed 2020-11-04

Suppliers 1

Companies that disclose Kite Pharma, Inc. as a major customer, as a share of their own revenue. 0 active, 1 lapsed.

Company	% of their revenue	Est. $ from Kite Pharma, Inc.	Period	Trend	Status	Source
SGMOQ SANGAMO THERAPEUTICS, INC	13%	$7.5M	3M 2020-09-30	−21.0pp	Lapsed Last seen 2020-09-30	10-Q 2020-11-04
Kite Pharma, Inc. 13 % 40 % 24 % 55 % 10-Q filed 2020-11-04 Period 3M 2020-07-01 to 2020-09-30 (13%), 3M 2019-07-01 to 2019-09-30 (40%)Accession 0001628280-20-015504 Kite Pharma, Inc. 34 % 52 % 42 % 61 % 10-Q filed 2020-08-05 Period 3M 2020-04-01 to 2020-06-30 (34%), 3M 2019-04-01 to 2019-06-30 (52%)Accession 0001628280-20-011806 Kite Pharma, Inc. 55 % 75 % 10-Q filed 2020-05-11 Period 3M 2020-01-01 to 2020-03-31 (55%), 3M 2019-01-01 to 2019-03-31 (75%)Accession 0001628280-20-007462 During 2018, revenues related to the hemophilia A collaboration agreement with Pfizer Inc. (“Pfizer”) and Kite Pharma, Inc. (“Kite”), a wholly-owned subsidiary of Gilead Sciences, Inc., represented 45% and 30%, respectively, of the Company’s total revenue. 10-K filed 2019-03-01 Period FY 2018-01-01 to 2018-12-31 (30%)Accession 0001564590-19-005808

Alerts are coming

Get an email when Kite Pharma, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.